Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niravoline SCHEMBL7935616 | 1.00 | SIGMAR1 (0.67) | SIGMAR1OPRK1OPRM1OPRD1 | |
| Niravoline SCHEMBL29388767 | 1.00 | SIGMAR1 (0.67) | SIGMAR1OPRK1OPRM1OPRD1 | |
| Niravoline SCHEMBL9250990 | 1.00 | SIGMAR1 (0.67) | SIGMAR1OPRK1OPRM1OPRD1 | |
| Niravoline SCHEMBL7942442 | 0.99 | SIGMAR1 (0.66) | SIGMAR1OPRK1OPRM1OPRD1 | |
| Niravoline SCHEMBL7747722 | 0.99 | SIGMAR1 (0.66) | SIGMAR1OPRK1OPRM1OPRD1 | |
| SCHEMBL9260449 | 0.90 | SIGMAR1 (0.64) | SIGMAR1OPRK1OPRM1OPRD1 | |
| SCHEMBL9510530 | 0.90 | SIGMAR1 (0.64) | SIGMAR1OPRK1OPRM1OPRD1 | |
| SCHEMBL7966344 | 0.90 | SIGMAR1 (0.64) | SIGMAR1OPRK1OPRM1OPRD1 | |
| SCHEMBL9644180 | 0.90 | SIGMAR1 (0.64) | SIGMAR1OPRK1OPRM1OPRD1 | |
| SCHEMBL9512728 | 0.88 | SIGMAR1 (0.64) | SIGMAR1OPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017846-A1 | TOPICAL ANALGESICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-01-16 | — | — | US | claimed |
| US-20200054594-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MOR AGONIST AND KOR AGONIST, AND USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-02-20 | — | — | US | claimed |
| EP-3610874-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MOR AGONIST AND KOR AGONIST, AND USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-02-19 | — | — | EP | claimed |
| CN-109982699-A | A kind of medical composition and its use of MOR agonist and KOR agonist | 江苏恒瑞医药股份有限公司 | 2019-07-05 | — | — | CN | claimed |
| EP-3324975-A1 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | Hsu, John (US) | 2018-05-30 | — | — | EP | claimed |
| WO-2017015309-A1 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | HSU JOHN (US) | 2017-01-26 | — | — | WO | claimed |
| US-20170020885-A1 | Composition Comprising a Therapeutic Agent and a Respiratory Stimulant and Methods for the Use Thereof | HSU JOHN (US) | 2017-01-26 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-6468971-B1 | Maintaining kidney function during surgery or trauma | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2002-10-22 | — | — | US | claimed |
| US-5348971-A | Indanes useful as analgesics | ROUSSEL UCLAF (FR) | 1994-09-20 | — | — | US | claimed |
| EP-0374054-B1 | INDANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES OBTAINED, THEIR USE AS MEDICINES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1993-10-06 | — | — | EP | claimed |
| WO-2026101753-A1 | NALFURAFINE AND NALMEFENE AS KAPPA OPIOID RECEPTOR INACTIVATING THERAPEUTIC AGENTS | UNIVERSITY OF WASHINGTON (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-5348971-A | Indanes useful as analgesics | ROUSSEL UCLAF (FR) | 1994-09-20 | — | — | US | disclosed |
| EP-0374054-B1 | INDANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES OBTAINED, THEIR USE AS MEDICINES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1993-10-06 | — | — | EP | disclosed |
| EP-0374054-A1 | Indane derivatives, process for their preparation and intermediates obtained, their use as medicines, and pharmaceutical compositions containing them | ROUSSEL-UCLAF (FR) | 1990-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020885-A1 | Composition Comprising a Therapeutic Agent and a Respiratory Stimulant and Methods for the Use Thereof | OPRM1, OPRL1, OPRK1 | SIGMAR1 13/4885OPRK1 3/4885OPRM1 1/4885 |
| US-20200054594-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MOR AGONIST AND KOR AGONIST, AND USES THEREOF | OPRM1, OPRK1, OPRD1 | SIGMAR1 8/4885OPRK1 2/4885OPRM1 1/4885 |
| US-20250017846-A1 | TOPICAL ANALGESICS | OPRK1, OPRL1, OPRM1 | SIGMAR1 6/4885OPRK1 1/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.